Search / Trial NCT00000377

Preventing the Return of Depression in Elderly Patients

Launched by UNIVERSITY OF PITTSBURGH · Nov 2, 1999

Trial Information

Current as of December 27, 2024

Completed

Keywords

Aged Antidepressive Agents Depression Dose Response Relationship, Drug Female Human Male Middle Age Nortriptyline Placebos Recurrence Aged, 80 And Over Antidepressive Agents *Therapeutic Use Antidepressive Agents Administration & Dosage Depression *Drug Therapy Nortriptyline *Therapeutic Use Nortriptyline Administration & Dosage

ClinConnect Summary

To determine whether elderly (60-80 years old) depressed patients who cannot sustain a remission without medication must be maintained at full acute-treatment dose. To compare the efficacy of full-dose vs half-dose nortriptyline (NT) in preventing recurrences of major depression in the elderly. To determine whether those patients who experience a recurrence while in a maintenance placebo condition (Study I) require 100 percent of their acute-treatment dose of NT to prevent subsequent recurrences or can be successfully maintained on 50 percent of their acute-treatment dose (Study II).

Inves...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • -
  • Patients must have:
  • Recurrence of major depression while in a maintenance placebo condition in the currently funded maintenance therapy protocol (Study I).

Trial Officials

Charles Reynolds, MD

Principal Investigator

About University Of Pittsburgh

The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials